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Abstract 
Desmoid tumors are rare benign monoclonal fibroblastic tumors. Their aggressiveness is local with no potential for 
metastasis or dedifferentiation. Here we report on a 61‑year‑old patient who presented a locally advanced breast 
desmoid tumor diagnosed 20 years after post‑operative radiotherapy for breast carcinoma. After 2 years of medical 
treatment, a high‑grade undifferentiated pleomorphic soft tissue sarcoma arose within the desmoid tumor. Despite 
extensive surgery removing both tumors, the patient showed locoregional relapse by the sarcoma, followed by 
multimetastatic progression, then death 25 months after the surgery. The arising of a soft tissue sarcoma in a desmoid 
tumor is an exceptional event since our case is the fourth one reported so far in literature. It reinforces the need for 
timely and accurate diagnosis when a new mass develops in the region of a preexisting desmoid tumor, and more 
generally when a desmoid tumor modifies its clinical or radiological aspect.
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Background
Desmoid tumors (DT) are rare benign monoclonal fibro-
blastic tumors representing less than 5 % of all soft tissue 
tumors [1]. Also called aggressive deep-seated fibroma-
tosis, they typically arise from muscular or aponeurotic 
structures. Their location may be extra-abdominal [2] 
or in the abdominal wall, usually sporadic, or intra-
abdominal [3], often associated with familial adenoma-
tosis polyposis (FAP) [1]. The mammary location is very 
rare (<10  % of all cases), the literature being limited to 
case reports and three retrospective series totalizing 81 
patients [4–6]. Such location does not seem to differ in 
term of clinical outcome than other locations.
Desmoid tumors grow slowly. Their aggressiveness is 
local with no potential for metastasis or dedifferentia-
tion. In the last 2012 World Health Organization (WHO) 
classification of sarcomas, they are classified as tumors 
with intermediate malignancy potential. Locally, they can 
damage vital structures and threaten life [7], notably in 
intra-abdominal locations, and have a high rate of recur-
rence even after complete resection. Their treatment 
remains challenging, based on diverse strategies [7, 8]: 
“wait-and-see policy”, non-steroidal anti-inflammatory 
drugs (NSAIDs), hormone therapy, chemotherapy and 
recently investigational targeted therapies (imatinib, 
sorafenib, pazopanib), and surgery and/or radiation ther-
apy. Their natural history is not well-defined and poorly 
understood, including long periods of stabilization, or 
even spontaneous regression.
The arising of a soft tissue sarcoma in a DT is an excep-
tional event, with only three cases reported to date [9–
11]. Here we report on a 61-year patient who presented 
a locally advanced breast DT refractory to multiple sys-
temic therapies and in which arose a rapidly lethal high-
grade undifferentiated soft tissue sarcoma.
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Case presentation
Description of the case
In April 2010, a 61-year-old woman, Caucasian type, 
presented inflammation of the right breast with indura-
tion and palpable mass in its medial part. The biopsy was 
negative. In October 2010, the breast MRI showed an 
8-cm tumor infiltrating the whole mammary gland and 
the pectoralis muscle, with enhancement after injection 
and skin thickening. The biopsy showed an “extensive 
and collagenic extensive fibrosis”. The patient was thus 
referred to our institution in December 2010.
The clinical examination showed a firm, 8-cm mass, in 
the medial part of the right breast, poorly circumscribed. 
There was no palpable axillary and supra-clavicular 
lymph node. The left breast was normal. The WHO per-
formance status was equal to 0. No history of personal 
or familial adenomatous polyposis or DT was present, 
but she had been treated 20  years earlier for an in  situ 
lobular adenocarcinoma of right breast with conserva-
tive surgery and adjuvant radiotherapy (60  Gy/30 frac-
tions). Breast MRI revealed spread infiltration of breast 
and pectoralis muscle (Fig.  1a). An ultrasound-guided 
biopsy was done. Pathological analysis (Fig. 1b) revealed 
a poorly cellular proliferation of myofibroblastic spindle 
cells, without histological evidence of malignancy (no 
atypia, no mitosis, no necrosis). Immunohistochemistry 
(IHC) showed strong nuclear expression of β-catenin by 
tumor cells, but no expression of desmin, H-caldesmon, 
S100 protein, MDM2, CDK4, AE1/AE3 cytokeratins and 
hormonal receptors. Histology was reviewed within the 
French Sarcoma Network (Réseau de Référence en Pathol-
ogie des Sarcomes, RRePS) and the diagnosis of mammary 
DT was retained, confirmed by the evidence of β-catenin 
exon 3 T41A mutation.
Given the tumor volume, no surgery was performed. 
A first-line systemic treatment combining celecoxib and 
high-dose tamoxifen was instituted. After 3-month treat-
ment, the tumor progressed and a second-line treatment 
based on polychemotherapy (doxorubicin-dacarbazine) 
was delivered for 6 cycles, leading to disease stabiliza-
tion. Imatinib-based third-line treatment was started 
on December 2011 because of disease progression, but 
prematurely stopped because of digestive toxicity. On 
February 2012, the disease locally progressed: a fourth-
line treatment based on the intra-venous methotrexate-
vinblastine combination was started without any clinical 
benefit after 3-months treatment. Aromatase inhibitor 
was delivered from May 2012. Due to disease progres-
sion on September 2012, sorafenib treatment was started, 
quickly stopped because of major skin toxicity, and thus 
replaced by sunitinib leading to disease stabilization dur-
ing 2 months.
On January 2013, the tumor modified its clinical 
aspect with further volume increase and appearance of 
a multilobulated aspect with a fine and tense skin over 
the tumor lobules, suggestive of a likely underlying sar-
coma. The performance status was equal to 1. Breast 
MRI showed the appearance of a 2-cm tissue mass in the 
upper-inner quadrant within the DT (Fig. 2). Surgery was 
decided. On February 2013, the patient underwent a wide 
Fig. 1 Mammary desmoid tumor: radiological and pathological aspects. a Breast MRI of January 2011: T1‑weighted Fat Sat images of the right 
breast after gadolinium injection. The white star shows the desmoid tumor. b Microscopic aspect (hematoxylin and eosin staining, HES) of the 
diagnostic biopsy showing a poorly cellular proliferation of bland elongated cells in a collagen‑rich stroma. Proliferation infiltrates adipose tissue 
(right upper corner)
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chest wall surgical resection including the whole right 
breast, the third to sixth right ribs, the right half of ster-
num associated with reconstruction. The macroscopic 
pathological report described a white mass with a hard 
consistency, an aspect sometimes fasciculated, realizing 
subcutaneous nodules (Fig.  3a). An ill-defined fibrous-
like area occupied most of the specimen, with contact 
to resection margin. Within this lesion, two less fibrous 
areas were identified. Microscopic analysis revealed two 
lesions (Fig. 3b–d): the DT, with spindle cell proliferation 
of fibroblast-like cells, without atypia, without mitosis, 
nor necrosis, interspersed within a dense collagenous 
matrix, contrasting with a high-grade sarcoma in the two 
less fibrous areas showing a more cellular and dense pro-
liferation of spindle cells disposed in sheets infiltrating 
the skeletal muscle bundles, with indistinct cytoplasmic 
limits, atypia and numerous mitoses. Resection margins 
were tumor-free for sarcoma, but involved for DT. No 
adjuvant treatment was delivered.
During follow-up, on June 2013, the CT scan showed 
the appearance of a suspect 2-cm pleural nodule in the 
operative field (Fig.  4a). The nodule increased to 5  cm 
on August and was biopsied, showing relapse by a high-
grade undifferentiated spindle-cell sarcoma with strong 
mitotic index. CT scan also showed the appearance of 
several subcutaneous nodules of chest wall. This relapse 
was stabilized by 8 cycles of chemotherapy (gemcitabine-
docetaxel regimen). Maintenance chemotherapy based 
on oral metronomic cyclophosphamide was started, but 
the disease worsened locally on April 2014, leading to 
Fig. 2 Appearance of a tumor within the desmoid tumor: radiological aspect. Breast T1‑weighted Fat Sat MR imaging of middle (top) and upper 
(bottom) sections of the right breast after gadolinium injection in January 2001 (a) and in January 2013 (b). The desmoïd tumor (white star) increased 
in size between the two dates. Surprisingly, a 2‑cm tissue mass (white arrow), corresponding to an undifferentiated sarcoma, appeared in the upper-
inner quadrant within the desmoid tumor in January 2013
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palliative radiotherapy targeting the cutaneous and sub-
cutaneous nodules of the right anterior chest wall. On 
September 2014, loco-regional progression involving the 
right anterior chest wall and the liver was documented on 
CT scan (Fig. 4b). Oral etoposide was started on October 
2014. Despite treatment, the disease further worsened 
and the patient died on March 2015.
Discussion
We report an exceptional case of soft tissue sarcoma 
arising in a refractory and locally advanced DT. As usu-
ally observed at the time of diagnosis of mammary DT 
[5], our patient was older than patients with abdominal 
location and the stage was advanced. Given the tumor 
volume, the initial treatment was medical, and during 
almost 2 years, the patient received successively NSAIDs, 
two regimens of hormone therapy, two regimens of 
chemotherapy and three targeted therapies without suc-
cess. After 2  years of treatment, a suspect modification 
of the clinico-radiological aspect led to surgery. Patho-
logical analysis of the operative specimen discovered a 
high-grade undifferentiated soft tissue sarcoma within 
the DT. Such pleomorphic sarcomas (ex-MFH, malig-
nant fibrous histiocytoma) are typically deep-seated and 
aggressive tumors with both local and metastatic risks 
[12]. Four months after surgery, the patient showed 
locoregional relapse by the sarcoma, initially sensitive to 
gemcitabine-docetaxel, followed by multimetastatic pro-
gression refractory to several therapeutic lines, leading to 
the death 25 months after the surgery.
To our knowledge, this is the fourth case of sarcoma 
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Fig. 3 Pathological aspect of the surgical specimen containing the desmoid tumor and the sarcoma. a Macroscopic aspect: an ill‑defined fibrous‑
like area occupies most of the specimen, with contact to resection margin (arrow). Within this lesion two less fibrous areas are identified (black lines). 
These ones correspond to high‑grade sarcoma zones on microscopic examination. b Microscopic aspect (HES) showing abrupt transition between 
high grade sarcoma (left) and DT (right). c Microscopic aspect (HES) showing the DT: spindle cell proliferation of fibroblastic‑like cells, interspersed 
within a collagenous matrix. Spindle cells are void of cytological atypia, and no mitosis or necrosis are seen. d Microscopic aspect (HES) showing the 
high grade sarcoma area. The neoplastic proliferation is more cellular and dense. Spindle cells are disposed in sheets infiltrating the skeletal muscle 
bundles. They appear small with indistinct cytoplasmic limits; nuclei are oval or round and display dense chromatin. Mitoses are easily found (black 
arrow)
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first one in a breast DT. In the first case report published 
more than 50 years ago [9], a 19-year-old woman, with-
out medical history, was operated for an inguinal 13-cm 
DT. During follow-up, she presented a local relapse 
treated with a total of four courses of radiotherapy over 
an 18-month period. Nine years after the last course, 
she presented a sudden increase in growth and cutane-
ous ulceration of the locally recurrent DT. Biopsy of this 
15-cm mass identified a fibrosarcoma. Histopathologic 
examination of the surgical resection specimen showed a 
5-cm high-grade fibrosarcoma surrounded by the DT. Six 
months after surgery, a local relapse of the fibrosarcoma 
occurred, requiring amputation. Following the ampu-
tation, several local recurrences were observed treated 
with surgery, then radiotherapy. Twenty months after 
amputation, the patient died. The second case [10] is a 
53-year-old man, with significant history of Milroy’s dis-
ease (chronic hereditary lymphedema of unknown ori-
gin). He presented a non-tender 14-cm DT in the medial 
malleolar region, without any functional limitation, diag-
nosed by open biopsy. Given the infiltrative nature of the 
lesion and the minimal clinical symptoms, observation 
was decided. Two weeks after the biopsy, a small raised 
skin lesion appeared posterior to the open biopsy inci-
sion. A punch biopsy showed aspect consistent with DT. 
Three months later, a dramatic increase in the posterior 
mass occurred with a fungating and necrotic aspect; the 
radiological evaluation showed the previously-identified 
DT, as well as the new large fungating mass associated 
to one additional small area of abnormal signal within 
the DT. Biopsy of the fungating tumor identified a high-
grade undifferentiated pleomorphic sarcoma, leading to 
below-knee amputation. The pathological analysis of the 
operative specimen showed the DT, which contained 
the two nodular masses corresponding to the undif-
ferentiated sarcoma. Surgical margins were negative for 
sarcoma but microscopically positive for DT. Ten years 
after amputation, the patient was alive with no evidence 
of disease. The third case [11] is extracted from a series 
of eight patients in which the morphologic changes seen 
after radiotherapy in desmoid-type fibromatosis were 
retrospectively studied. The patient was a 12-year-old 
boy with initially a 9.5-cm DT of the proximal part of 
the upper limb treated by surgery. He presented a local 
relapse 36  months later that was treated with external 
radiotherapy (dose between 50 and 60 Gy). Sixteen years 
later, he underwent forequarter amputation because of a 
clinical progression of the tumor: the pathological anal-
ysis of the operative specimen demonstrated areas of 
fibrosarcoma with zonal necrosis, hypercellularity, severe 
nuclear atypia, and increased mitotic activity, adjacent to 
the locally recurrent DT. Three months after amputation, 
the patient was alive with no evidence of disease.
In summary, in all informative cases, the diagnosis of 
sarcoma was suspected by clinical modifications of the 
DT (volume increase, ulceration, multilobulated aspect) 
associated with radiological modifications with appear-
ance of nodular masses within the DT. But these signs 
are not specific, and given the very exceptional character 
of sarcomatous degeneration of DT, the pre-therapeutic 
diagnostic confirmation was attempted in only one case, 
the diagnostic being done after surgery in the three other 
cases. Like for any soft tissue sarcoma, the treatment was 
margin-free monobloc surgery.
In pathophysiological term, in all cases, the sarcoma 
appeared within the DT and a specific risk factor for 
Fig. 4 Relapse of the high‑grade sarcoma: radiological aspect. a CT‑scan in June 2013 showed the appearance of a 2‑cm right pleural nodule in 
the operative field (white arrow). The percutaneous biopsy achieved 2 months later will identify high‑grade undifferentiated spindle‑cell sarcoma. b 
Major disease progression in September 2014, involving the pleura, the right anterior chest wall and the liver
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developing sarcoma was present: Milroy’s disease in 
one case [9], and radiotherapy in the three others ones 
with an interval between radiotherapy and sarcoma 
diagnosis of 9  years [9], 16  years [11], and 22  years 
(our case). In the two first cases, the radiotherapy was 
delivered in order to treat the DT, whereas in our case, 
it was delivered after surgery of breast cancer 20 years 
before the diagnosis of DT. In the absence of molecular 
analyses, it is not possible to know whether a common 
genetic mutation could explain the coexistence of DT 
and soft tissue sarcoma. Classically, the pleomorphic 
undifferentiated sarcomas display a complex genetic 
profile without specific structural alteration, whereas 
DTs display a simple genomic profile with specific 
mutation. The search for a common molecular altera-
tion in both entities might benefit from the new next-
generation sequencing techniques. Regarding the cell 
of origin, the embryologic derivation of the fibroblast 
(the mesoderm) renders it capable of giving rise, under 
appropriate oncogenic influences, to a wide range of 
proliferative manifestations [13] including for example 
aggressive fibromatosis, fibrosarcoma arising in a keloid, 
dermatofibrosarcoma protuberans, malignant fibrous 
histiocytoma, and also one case of aggressive fibromato-
sis progressing over 3 years to poorly differentiated sar-
coma with widespread metastases, which may suggest 
a progressive increase in the malignant potential of the 
fibroblasts in the patient’s tumor.
Conclusion
We report the fourth case of soft tissue sarcoma arising in 
a DT. This case reinforces the need for timely and accu-
rate diagnosis when a desmoid tumor modifies its clinical 
or radiological aspect, notably in presence of associated 
risk factors such as history of radiotherapy. Given the 
exceptional nature of such diagnosis, case reports such as 
this one serve as the only reference for clinicians taking 
care of these patients.
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